VGIT vs XBI
Vanguard Intermediate-Term Treasury ETF vs SPDR S&P Biotech ETF
VGIT$58.66
Vanguard Intermediate-Term Treasury ETF
Intermediate-term US Treasuries (3–10 years).
Expense: 0.03%Yield: 3.85%
XBI$164.01
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.36%
Quick take
- • VGIT has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VGIT pays a higher dividend yield (3.85%).
Side-by-side metrics
| Metric | VGIT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.85% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $50.38B | $10.73B |
YTD return | -0.48% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.78 | 1.10 |
P/E ratio | — | — |
Last price | $58.66 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
VGIT top holdings
Holdings data unavailable for VGIT.
XBI top holdings
Top holdings · XBI
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
Sector breakdown · XBI
Financial Services0.5%
Healthcare99.5%
About VGIT
VGIT (Vanguard Intermediate-Term Treasury ETF) is Intermediate-term US Treasuries (3–10 years). Managed by Vanguard, the fund carries $50.4B in assets under management, an expense ratio of 0.03%, a dividend yield of 3.85%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.